Aagami has completed 40+ one-on-one strategic meetings at Biotech Showcase which started during JPM week in January. As the meetings are online this t...
Published : 02 Feb 2021
Read MorePlease note that effective November 01, 2020, our office address has reverted to:Aagami Inc.2020 Calamos Court, Suite 200Naperville, Illinois 60563USA...
Published : 03 Nov 2020
Read MoreAagami is appointed by a Clinical stage French Pharma developing a smoking cessation drug extracted from natural tobacco leaf , for support...
Published : 23 Sep 2020
Read MoreAagami has been appointed by a Portugal headquartered Pharmaceutical Company dedicated to helping Pharmaceutical Customers bring new and off-patent dr...
Published : 18 Sep 2020
Read MoreAagami has succeeded in establishing a partnership for its Australian client which has a proven technology for producing high value(multi-billion doll...
Published : 28 Aug 2020
Read MoreWe have a new client, new assignment. A Texas based Pharma has appointed Aagami for divesting 2 oncology assets.The client, after acquiring a nov...
Published : 13 Aug 2020
Read MoreA Silicon Valley based company has appointed Aagami to support their investment needs. The client is developing and commercializing a ma...
Published : 24 Jul 2020
Read MoreAn Oakland, California based medical technology start-up developing the portable single-sided MRI, has appointed Aagami for supporting their need for ...
Published : 23 Jun 2020
Read MoreA Japanese company has chosen Aagami to partner with marketing and selling companies from the US, India and across the world for their on the market p...
Published : 02 Jun 2020
Read MoreAagami has received an assignment from a French company developing a natural tobacco leaf extracted drug for smoking cessation. Only 2 injections for ...
Published : 19 May 2020
Read More